[PDF] academia.edu

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and …

N Harbeck, RE Kates, MP Look, ME Meijer-van Gelder… - Cancer research, 2002 - AACR
Risk assessment and prediction of response to treatment are prerequisites for individualized
adjuvant therapy decisions in breast cancer. The strong prognostic impact of the two …
Save Cite Cited by 320 Related articles All 7 versions
[PDF] academia.edu

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

…, R Bell, J Bergh, R Coleman, A Wardley, N Harbeck… - The lancet, 2007 - thelancet.com
Background Trastuzumab—a humanised monoclonal antibody against HER2—has been
shown to improve disease-free survival after chemotherapy in women with HER2-positive …
Save Cite Cited by 1953 Related articles All 18 versions
[HTML] nejm.org

[HTML][HTML] Pembrolizumab for early triple-negative breast cancer

…, C Denkert, YH Park, R Hui, N Harbeck… - … England Journal of …, 2020 - Mass Medical Soc
Background Previous trials showed promising antitumor activity and an acceptable safety
profile associated with pembrolizumab in patients with early triple-negative breast cancer. …
Save Cite Cited by 1891 Related articles All 13 versions
[HTML] nejm.org

[HTML][HTML] Overall survival with ribociclib plus endocrine therapy in breast cancer

SA Im, YS Lu, A Bardia, N Harbeck… - New England journal …, 2019 - Mass Medical Soc
Background An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent
kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit …
Save Cite Cited by 889 Related articles All 15 versions
[HTML] nejm.org

[HTML][HTML] Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer

…, P Vitazka, G Meinhardt, N Harbeck… - … England Journal of …, 2022 - Mass Medical Soc
Background Among breast cancers without human epidermal growth factor receptor 2 (HER2)
amplification, overexpression, or both, a large proportion express low levels of HER2 that …
Save Cite Cited by 1119 Related articles All 19 versions
[HTML] nejm.org

[HTML][HTML] Event-free survival with pembrolizumab in early triple-negative breast cancer

…, C Denkert, YH Park, R Hui, N Harbeck… - … England Journal of …, 2022 - Mass Medical Soc
Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …
Save Cite Cited by 581 Related articles All 12 versions
[HTML] nejm.org

[HTML][HTML] Palbociclib and letrozole in advanced breast cancer

…, S Jones, SA Im, K Gelmon, N Harbeck… - New England journal …, 2016 - Mass Medical Soc
Background A phase 2 study showed that progression-free survival was longer with palbociclib
plus letrozole than with letrozole alone in the initial treatment of postmenopausal women …
Save Cite Cited by 2548 Related articles All 10 versions
[HTML] sciencedirect.com

[HTML][HTML] Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast …

…, M Gnant, A Goldhirsch, P Goodwin, N Harbeck… - Annals of oncology, 2015 - Elsevier
The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial
new evidence on locoregional and systemic therapies for early breast cancer. Further …
Save Cite Cited by 2225 Related articles All 23 versions
[PDF] uclouvain.be

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer …

…, T Luis, B Jens-Uwe, F Peter, F Dirk, H Nadia… - The Lancet, 2020 - thelancet.com
Background Pembrolizumab monotherapy showed durable antitumour activity and manageable
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …
Save Cite Cited by 1207 Related articles All 15 versions
[PDF] sciencedirect.com

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on …

…, S Loi, S Verma, H Iwata, N Harbeck… - The Lancet …, 2016 - thelancet.com
Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor
palbociclib and fulvestrant was associated with significant improvements in progression-free …
Save Cite Cited by 1737 Related articles All 17 versions